Loading stock data…
CTEV
$24.93+0.60 (+2.47%)
Market ClosedLast close May 1
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CTEV in the Healthcare sector is trading at $24.93. The stock is currently 66% below its 52-week high of $74.07, remaining 38.4% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why CTEV maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.93
Potential Upside
5%
Whystock Fair Value$26.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$39.80+59.6%
Range$21.00 – $90.00
Fundamentals
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$344.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
163.47%
Volume
Today's trading volume
52,036
Recent News
Concerns Surrounding AI Pressured Claritev Corp (CTEV)
Third Point Management, a New York-based investment advisor, released its first-quarter 2025 investor letter. Third Point’s flagship Offshore Fund returned -0.6% in Q1 2026. The fund started the quarter strong with gains in semiconductors, memory, equipment, infrastructure, aerospace, and defense. A copy of the letter is available to download here. Despite profits and reducing exposures before […]
How The Claritev (CTEV) Narrative Is Shifting As Targets Fall And Growth Plans Evolve
Claritev’s updated fair value estimate has shifted from US$44.75 to US$42.75 per share, putting a finer point on where the current model sees the stock’s long term potential. That adjustment lines up with Street research that has pulled price targets into a US$21 to US$38 range, as analysts balance solid Q4 results and M&A investment plans against tighter expectations for 2026 guidance and execution. Read on to see what is driving this evolving narrative and how to keep track of the key...
How The Claritev (CTEV) Investment Story Is Shifting As Expectations And Valuation Reset
Claritev’s fair value price target has been reset from US$57.25 to US$44.75, a reduction of roughly 22% that marks a clear reset in expectations. Analysts are openly split on what this means, with some emphasizing Claritev’s role as a core vendor and others focusing on leverage, guidance uncertainty, and a wide range of price targets. Read on to see how these views are shaping the story around Claritev and how you can keep track as the narrative evolves. Stay updated as the Fair Value for...
Claritev Corp (CTEV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Claritev Corp (CTEV) reports a 6.2% revenue increase and outlines ambitious growth plans for 2026 amidst challenges.
Claritev Q4 Earnings Call Highlights
Claritev (NYSE:CTEV) used its fourth-quarter 2025 earnings call to highlight a year of improving financial performance, an acceleration in sales activity, and continued progress on what management described as a multi-year transformation plan under its “Vision 2030” strategy. The company also issued